At the recent American Society of Hematology (ASH) annual meeting, there were several presentations comparing a drug regimen of Velcade (bortezomib), thalidomide (Thalomid), and dexamethasone (Decadron), abbreviated as VTD, with a drug regimen of thalidomide and dexamethasone, abbreviated as TD, in newly diagnosed multiple myeloma patients.

Update: VTD Versus TD With Double Autologous Stem Cell Transplantation

One of the ASH presentations showed that the addition of Velcade to a thalidomide-dexamethasone regimen and double autologous stem cell transplantation significantly improves the response rate in newly diagnosed multiple myeloma …

A new study suggests that NPI-0052 (marizomib), a new product being developed by Nereus Pharmaceuticals, Inc., may be more active and less toxic in patients with relapsed or refractory myeloma despite treatment with Velcade (bortezomib) and other drugs. Researchers presented the preliminary results of the Phase 1 trial on December 7 at the 51st annual meeting of the American Society of Hematology (ASH).

Found in marine bacteria, NPI-0052 acts, like Velcade, as a proteasome inhibitor. Both compounds prevent enzymes in cancer cells that regulate growth from working properly, which …

The results from a new study indicate that treatment of newly diagnosed multiple myeloma with novel therapeutic agents improves kidney function in most patients, in comparison to treatment with conventional chemotherapy and a high-dose regimen of dexamethasone (Decadron). The authors of the study presented the results of the clinical trial on December 8 at the 51^st American Society of Hematology (ASH) Annual Meeting and Exposition.

Multiple myeloma patients commonly experience complications with kidney function, and kidney impairment is associated with increased mortality rates. The Myeloma Beacon recently published a series …

The 2009 American Society of Hematology (ASH) Meeting showcased several presentations on Zolinza (vorinostat), a histone deacetylase inhibitor developed by Merck Pharmaceuticals that is currently investigated for the treatment of multiple myeloma.

Zolinza alters the way a cancer cell’s DNA creates proteins, which is important in cancer treatment because such a drug can slow down cell proliferation, minimize mutations in DNA and control cell death.

Zolinza With Revlimid And Dexamethasone

Preliminary data from an ongoing Phase 1 study suggest that the combination treatment of Zolinza, Revlimid (lenalidomide) and …

Results from recent Phase 1/2 clinical trials show that a perifosine, Velcade (bortezomib) and dexamethasone (Decadron) combination treatment is safe and effective for relapsed and refractory multiple myeloma. Perifosine is an alkyl-phosphocholine compound that controls cell division, cell growth and cell death, and is currently investigated for the treatment of multiple myeloma. Researchers presented their findings on December 5 at the American Society of Hematology’s 51^st Annual Meeting.

“Great meeting—lots of exciting new developments for multiple myeloma,” wrote Dr. Paul Richardson, lead researcher in the study, in an …

During this year’s meeting of the American Society of Hematology (ASH), there were several presentations about tanespimycin, a new drug currently being developed by Bristol-Myers Squibb and Kosan Biosciences. Tanespimycin inhibits Hsp90, which acts as a molecular chaperone for proteins critical to the growth, survival, and drug resistance of cancerous cells.  

Safety And Activity Profile Of Tanespimycin And Velcade From Phase 1/2 Study

One of the ASH presentations showed that the combination treatment of tanespimycin and Velcade (bortezomib) effectively targets Hsp90 in patients with relapsed or refractory multiple myeloma. The treatment …

Researchers from Canada have found that long exposure to novel agents as well as achievement of higher response rates contribute to long-term survival in multiple myeloma patients.  They presented their findings at the American Society of Hematology Meeting (ASH) on December 6.

The term “long-term survivor” refers to a person who is alive for ten or more years following diagnosis of myeloma. Long-term survival is still unusual in multiple myeloma. Less than 10 percent of patients fall into the category of long-term survivors.

Velcade (bortezomib), thalidomide (Thalomid) and Revlimid (lenalidomide) …